Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model
Sang Youb Han, Hye Kyoung Song, Jin Joo, Jee‐Young Han, Young Sun Kang, Dae Ryong
Topics & Concepts
Farnesoid X receptorEndocrinologyInternal medicineInsulin resistanceLipid metabolismKidneyAdipose tissueLiver X receptorMedicineDiabetes mellitusBiologyNuclear receptorTranscription factorGeneBiochemistryDrug Transport and Resistance MechanismsDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins